A future therapeutic strategy undertaking an unbiased screening approach to identify potent SorLA blocking antibodies might provide a way forward in targeting heregulin-driven activation of the HER2-HER3 dimer in breast cancer. Here, ERBB3 is linked to breast carcinoma.